stockrowThe Chemours Company
CC Basic Materials Specialty Chemicals
The Chemours Company’s revenue for fiscal 2025 (year ended December 2025) was $5.8 billion, roughly unchanged from fiscal 2024.
- Revenue
- +3.01%
- EPS
- +223.8%
- Free cash flow
- −12.5%
- Total debt
- −7.64%
Quarter to September 2026, against a year earlier
Follow CC
Alert me
The Chemours Company (CC) EPS (diluted)
The Chemours Company's EPS (diluted) for fiscal 2025 was −$2.56, compared with $0.46 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.02. Over the past ten years it has ranged from −$2.56 (fiscal 2025) to $5.45 (fiscal 2018) — the current reading is the lowest in ten years. The Chemours Company ranks 46th of 56 Specialty Chemicals companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$2.56 | — |
| FY2024 | $0.46 | — |
| FY2023 | −$1.70 | — |
| FY2022 | $3.65 | 1.39% |
| FY2021 | $3.60 | 172.73% |
| FY2020 | $1.32 | — |
| FY2019 | −$0.32 | — |
| FY2018 | $5.45 | 39.39% |
| FY2017 | $3.91 | 9,675.00% |
| FY2016 | $0.04 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.29 | — |
| Jun 2026 | −$1.81 | — |
| Mar 2026 | −$0.19 | — |
| Dec 2025 | −$0.31 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| WDFC WD-40 Company compare | $6.08 |
| IOSP Innospec Inc. compare | $5.66 |
| KWR Quaker Houghton compare | $5.59 |
| FUL H. B. Fuller Company compare | $3.59 |
| NGVT Ingevity Corporation compare | $1.47 |
| SCL Stepan Company compare | $0.19 |
| CC The Chemours Company | −$1.02 |
| MTX Minerals Technologies Inc. compare | −$2.14 |
| STDN Standard Nuclear Inc compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on CC
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement